BioSpace News Archive

Aldeyra Therapeutics reported that its reproxalap hit the mark in the Phase III Tranquility-2 study for dry eye disease. The drug showed statistical superiority for its two primary endpoints.

UCLA researchers report gene therapy may correct a rare creatine deficiency disorder that results in intellectual disabilities, issues with speech, involuntary movements and recurrent seizures.

South San Francisco-based Rigel Pharmaceuticals reported its Phase III Forward trial of fostamatinib did not show statistical significance in warm autoimmune hemolytic anemia

Funding this week went mostly to companies with sophisticated tech platforms. Financing rounds will support platforms for tumor-targeting antibodies, genome-scale nucleic and acid imaging.

Sales and marketing roles in the life sciences field are in high demand. To help with your job search, we’ve compiled a guide to sales and marketing jobs in the life sciences industry.

Novo Nordisk and Eli Lilly came under legal scrutiny this week, while BMS forked over $11 million to settle claims over anticompetitive tactics.

At ENDO 2022, Ascendis will share Phase II and III data showing clinical efficacy for its investigational product candidate for hypoparathyroidism. For this and more, see inside.

The new space will enable Astellas to establish a global supply chain of gene therapies as well as widen the scope of the therapeutic products it creates.

Q32 Bio announced that its Founder and Chief Scientific Officer, Shelia Violette, Ph.D., will present “Targeting Complement in Chronic Inflammatory Disease” at the “Resolution of Inflammation” conference, and is the co-organizer of the “Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies” conference, at the Keystone Symposia on Molecular and Cellular Biology, taking place June 12 through June 16, 2022.

Conference call and webcast to be held today at 8:00 a.m. Eastern Time.